RxDoctor Payments Data

Michael Mall, MD

Family Medicine · Las Vegas, NVNPI 1972513091

Payments from drug & device makers

$2,581in general payments, 2019–2025

Across 125 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$614
  • Otsuka America Pharmaceutical, Inc.$364
  • Merz North America, Inc.$305
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$203
  • Amgen$187
  • Amarin Pharma, Inc.$133
  • plus $775 from 17 others

What the payments were for

  • Food & beverage$2,47296%
  • Education$1094%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,581 in reported general payments places this provider in the 80th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$354,679
Medicare patients
88
Services billed
728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin30$36,374
XareltoRivaroxaban12$15,390
TrintellixVortioxetine Hydrobromide13$11,004
Liothyronine Sodium105$8,974
PremarinEstrogens, Conjugated29$6,122
Sirolimus11$5,757
Omega-3 Acid Ethyl Esters42$3,891
Celecoxib56$2,138
Calcitonin-SalmonCalcitonin,salmon,synthetic20$2,095
ProgesteroneProgesterone, Micronized41$1,856
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$1,665
Levothyroxine Sodium130$1,284
Metformin Hcl142$1,163
Tamsulosin Hcl29$785
Dutasteride11$715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$35$15,39012 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$40$11,00413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →